Evotec (EVO) Competitors $4.23 +0.03 (+0.71%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$4.22 -0.01 (-0.24%) As of 05/1/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. AXSM, NUVL, VRNA, GRFS, KRYS, ADMA, CYTK, ELAN, PCVX, and RYTMShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Vaxcyte (PCVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Axsome Therapeutics Nuvalent Verona Pharma Grifols Krystal Biotech ADMA Biologics Cytokinetics Elanco Animal Health Vaxcyte Rhythm Pharmaceuticals Axsome Therapeutics (NASDAQ:AXSM) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings. Which has stronger earnings and valuation, AXSM or EVO? Evotec has higher revenue and earnings than Axsome Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$385.69M14.19-$287.22M-$5.99-18.74Evotec$796.97M1.88-$90.82MN/AN/A Does the media refer more to AXSM or EVO? In the previous week, Axsome Therapeutics had 10 more articles in the media than Evotec. MarketBeat recorded 16 mentions for Axsome Therapeutics and 6 mentions for Evotec. Axsome Therapeutics' average media sentiment score of 1.20 beat Evotec's score of 0.22 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate AXSM or EVO? Axsome Therapeutics presently has a consensus target price of $169.87, suggesting a potential upside of 51.34%. Evotec has a consensus target price of $5.93, suggesting a potential upside of 40.27%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00Evotec 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals believe in AXSM or EVO? 81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is AXSM or EVO more profitable? Evotec has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. Evotec's return on equity of 0.00% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-74.47% -223.51% -39.88% Evotec N/A N/A N/A Does the MarketBeat Community prefer AXSM or EVO? Axsome Therapeutics received 474 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 70.59% of users gave Axsome Therapeutics an outperform vote while only 50.00% of users gave Evotec an outperform vote. CompanyUnderperformOutperformAxsome TherapeuticsOutperform Votes48070.59% Underperform Votes20029.41% EvotecOutperform Votes650.00% Underperform Votes650.00% Which has more risk and volatility, AXSM or EVO? Axsome Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. SummaryAxsome Therapeutics beats Evotec on 10 of the 16 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50B$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales1.88241.49397.62103.30Price / Cash161.0865.8538.1834.62Price / Book1.246.486.734.25Net Income-$90.82M$143.41M$3.22B$248.18M7 Day Performance0.24%2.58%1.38%1.03%1 Month Performance30.96%5.00%2.79%2.70%1 Year Performance-21.23%-3.72%15.41%4.05% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.859 of 5 stars$4.23+0.7%$5.93+40.3%-19.4%$1.50B$796.97M0.004,200Upcoming EarningsShort Interest ↓AXSMAxsome Therapeutics4.832 of 5 stars$103.00-1.4%$169.80+64.9%+49.9%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsNUVLNuvalent1.8882 of 5 stars$69.95-2.4%$115.50+65.1%+7.9%$5.01BN/A-20.1640Upcoming EarningsPositive NewsVRNAVerona Pharma2.9026 of 5 stars$60.07+2.0%$75.43+25.6%+374.8%$4.85B$42.28M-31.2930Earnings ReportAnalyst ForecastInsider TradeShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.8946 of 5 stars$7.01-1.0%N/A+3.4%$4.82B$7.21B5.9926,300Short Interest ↓Positive NewsKRYSKrystal Biotech4.9043 of 5 stars$161.91-4.0%$220.00+35.9%+3.8%$4.68B$290.52M54.15210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsADMAADMA Biologics1.4611 of 5 stars$19.64-7.8%$22.50+14.6%+248.9%$4.64B$426.45M70.14530Upcoming EarningsOptions VolumeNews CoveragePositive NewsGap UpCYTKCytokinetics4.1714 of 5 stars$37.93-3.9%$81.63+115.2%-32.3%$4.52B$18.47M-7.05250Upcoming EarningsInsider TradeELANElanco Animal Health3.9364 of 5 stars$8.48+0.5%$14.67+73.0%-27.9%$4.21B$4.44B21.209,800Upcoming EarningsShort Interest ↑PCVXVaxcyte3.0309 of 5 stars$30.39-0.8%$136.50+349.2%-44.7%$3.91BN/A-6.61160Upcoming EarningsPositive NewsRYTMRhythm Pharmaceuticals3.7006 of 5 stars$60.48-2.0%$74.92+23.9%+54.0%$3.82B$130.13M-13.97140Upcoming EarningsInsider TradePositive News Related Companies and Tools Related Companies Axsome Therapeutics Alternatives Nuvalent Alternatives Verona Pharma Alternatives Grifols Alternatives Krystal Biotech Alternatives ADMA Biologics Alternatives Cytokinetics Alternatives Elanco Animal Health Alternatives Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EVO Stock Free EVO Stock Alerts